Shots:

• The P-III POETYK PSO-2 study involves assessing deucravacitinib (6mg- qd) vs PBO & Otezla (30mg- bid) in 1-020 patients with moderate to severe plaque psoriasis
• The trial met its co-1EPs & 2EPs demonstrating deucravacitinib was superior to Otezla (apremilast) in the patients reaching a PASI 75 and sPGA 0/1 @16wks. The overall safety profile of deucravacitinib was consistent with previously reported results
• Deucravacitinib is the first & only novel selective TYK2 inhibitor- currently being evaluated in psoriasis- PsA- lupus- and IBD

 ­ Ref: BMS | Image: BMS